Treatment intensity in locoregionally advanced head and neck cancer: recent investigation leads to new questions
- PMID: 35117096
- PMCID: PMC8798751
- DOI: 10.21037/tcr.2019.01.22
Treatment intensity in locoregionally advanced head and neck cancer: recent investigation leads to new questions
Conflict of interest statement
Conflicts of Interest: JA Bonner, MD: Occassional consultant/honoraria for Bristol-Myers Squibb Company, Eli Lilly and Company, Merck Serono, and Cel-Sci. DH Boggs, MD: Received honoraria and research support from Varian Medical System Inc. Received research support from Novocure Inc.
Figures
Comment on
-
Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial.J Clin Oncol. 2018 Jun 7:JCO2017762518. doi: 10.1200/JCO.2017.76.2518. Online ahead of print. J Clin Oncol. 2018. PMID: 29878867
References
-
- Tao Y, Auperin A, Sire C, et al. Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial. J Clin Oncol 2018:JCO2017762518.[Epub ahead of print]. - PubMed
-
- Wolf GT. Reexamining the Treatment of Advanced Laryngeal Cancer: The VA Laryngeal Cancer Study Revisited. Head Neck 2010;32:7-14. - PubMed
-
- Olsen KD. Reexamining the Treatment of Advanced Laryngeal Cancer. Head Neck 2010;32:1-7. - PubMed
Publication types
LinkOut - more resources
Full Text Sources